EUVIMEDEUVIMED entdecken
Open Access

COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies

Kai Chen, Kentaro Takeda iD, Ying Yuan iD

Statistics in Medicine · 2025

DOI: 10.1002/sim.70107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Kai Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Data Science, The University of Texas Health Science Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Project Optimus, initiated by the US Food and Drug Administration (FDA), seeks to shift the focus of dose finding and selection from the maximum tolerated dose to the optimal dose that offers the most favorable risk‐benefit balance. However, applying this paradigm shift to drug combination trials presents challenges, particularly due to limited sample sizes and a large two‐dimensional dose exploration space. These challenges are amplified when trials involve multiple indications. To address this, we developed a two‐stage Bayesian dose optimization design, called COMIC (Combination Optimization in Multiple IndiCations), to efficiently identify Optimal Biological Dose Combinations (OBDC) for multiple indications. The COMIC design follows a two‐stage strategy: First, optimizing the dose for one indication based on a utility function that measures the risk‐benefit tradeoff, and then using that data to inform and accelerate dose optimization for additional indications. This approach significantly reduces the required sample size. Additionally, we incorporate a pharmacodynamic endpoint (e.g., receptor occupancy) to prioritize which component of the combination should be escalated, further enhancing the efficiency of dose optimization. Simulation studies demonstrate the strong performance and robustness of the COMIC design across various scenarios. We illustrate the method using a CAR‐T therapy trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveBayes TheoremHumansComputer SimulationDose-Response Relationship, DrugMaximum Tolerated DoseUnited StatesDrug Therapy, CombinationUnited States Food and Drug AdministrationModels, StatisticalSample SizeClinical Trials as Topic

Stichwörter der Autor:innen

dose optimizationdrug combinationmultiple indicationsoptimal biological dose combinationsproject optimus

Autor:innen und Institutionen

  • Department of Biostatistics and Data Science, The University of Texas Health Science Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Astellas Pharma Global Development Inc., Northbrook, Illinois, USA.

ORCID-Profile: Kentaro Takeda, Ying Yuan

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Chen, K., Takeda, K., & Yuan, Y. (2025). COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies. Statistics in Medicine. https://doi.org/10.1002/sim.70107

Vancouver

Chen K, Takeda K, Yuan Y. COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies. Statistics in Medicine. 2025. doi:10.1002/sim.70107

BibTeX
@article{Chen2025,
  author = {Chen, Kai and Takeda, Kentaro and Yuan, Ying},
  title = {COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70107}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche